NCT05641129已完成不适用
Acute PresentatiOn of CoLorectaL Cancer: an internatiOnal Snapshot-An International, Multi-centre Study of Emergency Presentations of Colorectal Cancer
European Student Research Network1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2023年1月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2,000
- 试验地点
- 1
- 主要终点
- Primary outcome
研究概览
简要总结
APOLLO (Acute PresentatiOn of CoLorectaL Cancer: an internatiOnal snapshot) is an international, multi-centre, prospective observational study which will address this need and aims to describe the operative and non-operative management of emergency presentations of colon and rectal cancer in an international cohort.
详细描述
Primary aim: Describe the variation in the operative and non-operative management of emergency presentations of colon and rectal cancer in an international cohort.
Secondary aims:
- Identify risk factors for mortality (intraoperatively, at 30-days and at 90-days) and ostomy rates (at 30- and 90-days) in patients deemed for active management (i.e., not for palliative management) to develop a risk prediction model
- Validate risk criteria of large bowel obstruction in patients with previously known colorectal cancer undergoing neoadjuvant chemotherapy or awaiting elective surgery
Who?
- Patients aged 18 years and above presenting to the hospital acutely with colorectal cancer (CRC) for malignant large bowel obstruction (LBO), perforation, CRC-related haemorrhage or other reasons within the data collection periods. Both those managed with and without surgery will be included
- Patients with localised and metastatic disease will be included
- Patients with known colorectal cancer diagnoses will be included if they present acutely (e.g., with disease progression)
- Patients presenting acutely for the side effects of chemotherapy/radiotherapy of known cancers will be excluded
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient pathology: Patients admitted to the hospital acutely with primary colon AND/OR rectal adenocarcinoma and referred to general/colorectal surgical departments:
- •Patients who are operated on for curative/palliative treatment of colorectal cancer
- •Patients who are referred to general surgery for assessment (irrespective of if they proceed to surgery)
- •New diagnoses of colorectal cancer
- •Extent of cancer: All patients including extra-abdominal metastatic, intra-abdominal metastatic and non-metastatic disease
- •Known cancer: Patients presenting for the first time with colorectal cancer AND/OR known colorectal cancer diagnosis with progression of disease. i.e. obstruction of known colorectal cancer
- •Patient presentation: Symptomatic presentation of colorectal cancer i.e. large bowel obstruction, haemorrhage, perforation
排除标准
- •Presenting for side effects of cancer treatment
- •Patients with secondary cancers
- •Previously included in the study
结局指标
主要结局
Primary outcome
时间窗: 90-day
Mortality since day of presentation
次要结局
- Secondary outcome 2(30- and 90-day)
- Secondary outcome 5(90-day)
- Secondary outcome 3(30- and 90-day)
- Secondary outcome 6(30- and 90-day)
- Secondary outcome 1(30-day)
- Secondary outcome 4(30- and 90-day)
- Secondary outcome 7(30- and 90-day)
- Secondary outcome8(30- and 90-day)
- Secondary outcome 9(30- and 90-day)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Detection and Classification of Colon PolypsColon PolypsNCT00825292Mayo Clinic110
已完成
不适用
The Role of Tumor-associated Macrophages in Colorectal Liver MetastasesColorectal Liver MetastasesColorectal CancerLiver MetastasesImmunotherapyNCT03888638Humanitas Clinical and Research Center101
已完成
不适用
Complete Histologic Resection of Adenomatous Polyps?Adenomatous PolypsNCT01224444White River Junction Veterans Affairs Medical Center269
已完成
不适用
Detection of Colonic Polyps Via a Large Scale Artificial Intelligence (AI) SystemColonic PolypNCT04693078Shaare Zedek Medical Center100
Unknown
1 期
A Study of Picoplatin in Colorectal CancerColorectal CancerNCT00478946Poniard Pharmaceuticals43